Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcomes of retained and disengaged pregnant women living with HIV in Uganda.
Kiragga AN, Twinomuhwezi E, Banturaki G, Achieng M, Nampala J, Bagaya I, Kigozi J, Castelnuovo B, Musick BS, Hazra R, Yiannoutsos CT, Wools-Kaloustian KK. Kiragga AN, et al. Among authors: nampala j. PLoS One. 2021 May 21;16(5):e0251413. doi: 10.1371/journal.pone.0251413. eCollection 2021. PLoS One. 2021. PMID: 34019568 Free PMC article.
Decreased Dolutegravir and Efavirenz Concentrations With Preserved Virological Suppression in Patients With Tuberculosis and Human Immunodeficiency Virus Receiving High-Dose Rifampicin.
Sekaggya-Wiltshire C, Nabisere R, Musaazi J, Otaalo B, Aber F, Alinaitwe L, Nampala J, Najjemba L, Buzibye A, Omali D, Gausi K, Kengo A, Lamorde M, Aarnoutse R, Denti P, Dooley KE, Sloan DJ. Sekaggya-Wiltshire C, et al. Among authors: nampala j. Clin Infect Dis. 2023 Feb 8;76(3):e910-e919. doi: 10.1093/cid/ciac585. Clin Infect Dis. 2023. PMID: 35861296 Free PMC article. Clinical Trial.
Clinical Predictors of 3-Months Isoniazid Rifapentine (3HP) - Related Adverse Drug Reactions (ADR) During Tuberculosis Preventive Therapy. (PAnDoRA-3HP study): An Observational Study Protocol.
Sekaggya-Wiltshire C, Mbabazi I, Nabisere-Arinaitwe R, Banturaki G, Alinaitwe L, Otalo B, Aber F, Nampala J, Owor R, Bayiga J, Laker Agnes Odongpiny E, Castelnuovo B, Mayito J, Sekadde M, Pasipanodya JG, Turyahabwe S, Zawedde-Muyanja S. Sekaggya-Wiltshire C, et al. Among authors: nampala j. medRxiv [Preprint]. 2024 Jun 2:2024.06.01.24308310. doi: 10.1101/2024.06.01.24308310. medRxiv. 2024. PMID: 38853861 Free PMC article. Preprint.
"It is not easy": Experiences of people living with HIV and tuberculosis on Tuberculosis treatment in Uganda.
Nabisere-Arinaitwe R, Namatende-Sakwa L, Bayiga J, Nampala J, Alinaitwe L, Aber F, Otaalo B, Musaazi J, King R, Kesby M, Sloan DJ, Sekaggya-Wiltshire C. Nabisere-Arinaitwe R, et al. Among authors: nampala j. J Clin Tuberc Other Mycobact Dis. 2023 Jun 21;33:100385. doi: 10.1016/j.jctube.2023.100385. eCollection 2023 Dec. J Clin Tuberc Other Mycobact Dis. 2023. PMID: 38116575 Free PMC article.
Prevalence of COVID-19 infection in TB clinics in Kampala, Uganda.
Otaalo B, Cevik M, Mwebesa E, Nabisere-Arinaitwe R, Zawedde-Muyanja S, Nampala J, Nanziri C, Alinaitwe L, Aber F, Bayigga J, Nankinga B, Laker E, Owarwo NC, Sabiiti W, Adakun S, Kirenga B, Turyahabwe S, Sloan DJ, Sekaggya-Wiltshire C. Otaalo B, et al. Among authors: nampala j. Int J Tuberc Lung Dis. 2023 Jun 1;27(6):481-483. doi: 10.5588/ijtld.23.0010. Int J Tuberc Lung Dis. 2023. PMID: 37231596 No abstract available.
Treatment Strategy for Rifampin-Susceptible Tuberculosis.
Paton NI, Cousins C, Suresh C, Burhan E, Chew KL, Dalay VB, Lu Q, Kusmiati T, Balanag VM, Lee SL, Ruslami R, Pokharkar Y, Djaharuddin I, Sugiri JJR, Veto RS, Sekaggya-Wiltshire C, Avihingsanon A, Sarin R, Papineni P, Nunn AJ, Crook AM; TRUNCATE-TB Trial Team. Paton NI, et al. N Engl J Med. 2023 Mar 9;388(10):873-887. doi: 10.1056/NEJMoa2212537. Epub 2023 Feb 20. N Engl J Med. 2023. PMID: 36808186 Free PMC article. Clinical Trial.